bpc-157 human clinical trials safety regulatory status What do we know about 'research only' peptides? Q&A with expert Stuart Phillips bpc-157 human clinical trials evidence

2015 GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration BioMed Res Int Comprehensive analysis of GHK-Cu's role in stimulating collagen synthesis, ECM remodeling, and dermal repair through multiple signaling pathways

A 2024 pharmaceutical review in Pharmaceuticals raised tumorigenesis as a theoretical risk, though a 2025 response published in the same journal directly countered the concerns

OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship

However, retatrutide also carries higher GI side effect rates at these doses

However, there is evidence that BPC-157 is being illegally included in some wellness and anti-aging treatments and products (5)